Get notified of page updates
Education > XRAY > Search Results

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search by Topic Submit an Article for Review

All XRAYs

71 through 80 of 311

Relevance: Medium-High

Strength of Science: High

Research Timeline: Human Research

View Related Clinical Trials

Study : Risk-reducing ovarian cancer surgery and quality of life

Relevance: Medium-High

Strength of Science: High

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: People with an inherited BRCA mutation

People with an inherited BRCA gene mutation are recommended to have surgery to remove their ovaries before the age of natural menopause to reduce their risk of ovarian cancer.  This surgery can cause short-term and long-term effects. This study assesses the quality of life among people who have their fallopian tubes surgically removed and later have their ovaries removed compared to people who have their ovaries and fallopian tubes removed at the same time.  (Posted 7/26/22). Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

Study : A win for some patients with HER2-negative metastatic breast cancer

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

Most relevant for: People with HER2-low metastatic breast cancer

A drug used to treat HER2-positive breast cancer improved survival in people with metastatic breast cancers that were previously considered HER2-negative. These results change practice guidelines for metastatic breast cancer and reclassify HER2 tumor marker status as “HER2-low” to guide treatment. (Posted 7/18/22)

Update: On 08/05/2022 the FDA approved Enhertu to treat people with metastatic, HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or who developed disease recurrence during or within six months of completing chemotherapy. Enhertu is also approved for treatment of people with metastatic HER2-positive breast cancer who progressed after prior anti-HER2 treatment. Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : The hidden financial burden of treating cancer care symptoms

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People who are experiencing side effects due to cancer treatment or cancer.

Drugs commonly used to treat symptoms of cancer and cancer treatment side effects can cost thousands of dollars out of pocket for patients, depending on what drugs are used. (Posted 6/29/2022). Este artículo está disponible en español.

Read More

Relevance: Medium

Strength of Science: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Study : Do artificial sweeteners increase the risk of cancer?

Relevance: Medium

Strength of Science: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People who consume artificial sweeteners

A large study of adults in France suggests that artificial sweeteners may increase the risk of certain cancers. (posted 6/21/2022). Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Metastatic prostate cancer cases increased as screening use declined

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People who are concerned about their own or their loved one’s risk of prostate cancer

The number of people diagnosed with metastatic prostate cancer increased following a change in recommendations around the use of routine prostate cancer screening. (posted 6/13/22)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

View Related Clinical Trials

Article : Breast cancer risk for transgender men with inherited mutations

Relevance: Medium-High

View Related Clinical Trials

Most relevant for: Transgender men with an inherited mutation

There is little information related to the risks and treatment options for transgender men and nonbinary people who are at high-risk for breast cancer due to an inherited BRCA1 or BRCA2 mutation. We review an expert viewpoint on the implications of a BRCA mutation for transgender men undergoing breast removal as part of their gender-affirming care plan. (posted 5/19/22)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Update : New drug approved for metastatic prostate cancer

Relevance: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People who have been diagnosed with metastatic prostate cancer.

The FDA approved a new treatment for metastatic castration-resistant prostate cancer. They also approved a test that can be used to identify patients who would benefit from this new treatment.  (Posted 5/10/22)

Este artículo está disponible en español.

Read More

Relevance: Medium

Strength of Science: Medium-High

Research Timeline: Post Approval

Study : Increasing melatonin use raises concerns

Relevance: Medium

Strength of Science: Medium-High

Research Timeline: Post Approval

Most relevant for: people who take or consider taking melatonin to help with sleep.

Adult use of melatonin as a sleep aid has increased even though its benefits and risks are not well understood. This study looked at trends in melatonin use over the last 19 years. (Posted 4/14/2022)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : New tool to predict breast cancer risk for Black women

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Black women in the U.S.

An important part of making decisions about breast cancer screening and prevention is knowing your breast cancer risk. Specific tools are used to identify people who would benefit from early and/or additional screening and chemoprevention or those who would most benefit from genetic counseling and testing. Because these tools were developed using data mostly from white women, they are unable to predict cancer risk as well for Black women. To begin to address these gaps, researchers developed a new tool specifically designed to predict breast cancer risk for Black women. This tool has been shown to work well, especially for younger Black women. (posted 3/22/2022) Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : The chance of a second breast cancer is higher among some Hawai'ian women

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: women of Hawai’ian, Filipino or Asian American ancestry.

Women diagnosed with ductal carcinoma in situ (DCIS), an early form of breast cancer, are more likely to have a second breast cancer diagnosis if they are of Native Hawai'ian, Filipino or Japanese ancestry than women of other racial or ethnic groups. (posted 3/15/22)

Este artículo está disponible en español.

Read More